SAN
DIEGO, June 8, 2023 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company
committed to delivering a new class of RNA therapeutics called
Antibody Oligonucleotide Conjugates (AOCs™), today announced that
the company will be presenting two oral presentations and two
poster presentations at the 30th Annual FSHD Society International
Research Congress, being held June 15-16,
2023, in Milan, Italy.
ORAL PRESENTATIONS
June 15, 2023: 5:10 p.m. – 5:30 p.m.
CET
- Facioscapulohumeral Muscular Dystrophy (FSHD) Surgeries,
Cardiovascular Testing, Mobility Aids and Healthcare Utilization
After Diagnosis from a Real-World Data Analysis
June 16, 2023: 2:45 p.m. – 3:00 p.m.
CET
- Phase 1/2 Trial Evaluating AOC 1020 in Adults with FSHD:
FORTITUDE Trial Design
POSTER PRESENTATIONS
June 15-16, 2023: 12:30 p.m. – 2:00 p.m.
CET
- AOC 1020: An Antibody Oligonucleotide Conjugate (AOC) in
Development for the Treatment of FSHD
- Facioscapulohumeral Muscular Dystrophy (FSHD) Age-related
Differences in Symptoms Among Patients Over and Under
40-Years
Once available, the presentations and posters will be available
on the publications page of Avidity's website
at https://www.aviditybiosciences.com.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve
people's lives by delivering a new class of RNA therapeutics -
Antibody Oligonucleotide Conjugates (AOCs™). Avidity is
revolutionizing the field of RNA with its proprietary AOCs, which
are designed to combine the specificity of monoclonal antibodies
with the precision of oligonucleotide therapies to address targets
and diseases previously unreachable with existing RNA therapies.
Utilizing its proprietary AOC platform, Avidity demonstrated the
first-ever successful targeted delivery of RNA into muscle and is
leading the field with clinical development programs for three rare
muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular
dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
Avidity is broadening the reach of AOCs with its advancing and
expanding pipeline including programs in cardiology and immunology
through internal discovery efforts and key partnerships. Avidity is
headquartered in San Diego, CA. For more information
about our AOC platform, clinical development pipeline and people,
please visit www.aviditybiosciences.com and engage with us
on LinkedIn and Twitter.
Investor Contact:
Kathleen
Gallagher
(858) 401-7900 x550
investors@aviditybio.com
Media Contact:
Navjot
Rai
(858) 401-7900 x550
media@aviditybio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-announces-upcoming-presentations-at-the-30th-annual-fshd-society-international-research-congress-301845493.html
SOURCE Avidity Biosciences, Inc.